Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ascend Vitality vs EmbraceRX

Ascend Vitality
Graded #307

Higher grade

vs+2.299999999999997
EmbraceRX
Graded #363

Lower grade

The verdict

Ascend Vitality takes it — 60.9/100 to 58.6/100.

Ascend Vitality grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ascend Vitality is a cash-pay GLP-1 telehealth provider offering compounded semaglutide (starting at $199/mo) and compounded tirzepatide (starting at $299/mo) as both weekly injectables and needle-free…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAscend Vitality +5
50
45
Dose & formulationAscend Vitality +19
75
56
Clinical oversightEmbraceRX +2
74
76
Labs & monitoringEven
52
52
FulfillmentEmbraceRX +8
65
73
Contract termsEmbraceRX +18
37
55
Ascend Vitality · left barEmbraceRX · right bar

The numbers

MetricAscend VitalityEmbraceRX
WeighScore60.9/10058.6/100
GradeCC
Scorecard rank#307#363
Semaglutide$199/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Ascend Vitality

Graded #307 · C

Strengths

  • Both injectable and needle-free oral tablet forms of semaglutide and tirzepatide
  • LegitScript certified
  • Transparent cash-pay pricing with cancel-anytime subscription
  • Legal entity and address publicly disclosed (Ascend Vitality LLC, Sheridan, WY)

Where it loses points

  • All medications are compounded — FDA does not review compounded drugs for safety/effectiveness
  • No named compounding pharmacy partner disclosed
  • No public state-by-state availability list (homepage cites exclusions: LA, MS, KS, NM, WV)
  • Per-dose/titration pricing not published; only 'starting at' prices shown
EmbraceRX

Graded #363 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard